Market closed

Jade Biosciences/$JBIO

Jade Biosciences shares are trading lower after the company reported its Q1 2025 financial results and provided a corporate update.
3 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Jade Biosciences

Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Ticker

$JBIO
Trading on

Industry

Biotechnology

Employees

30

ISIN

US0080642061

Jade Biosciences Metrics

BasicAdvanced
$237M
-
-$18.79
-
$84.00
1,112.58%
$237M
$13.47
$7.42
$84.00
5.806
5.784
-229.929
-229.929
-0.81
-0.81
-0.835
1,112.58%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JBIO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Jade Biosciences stock?

What is the P/E ratio for Jade Biosciences stock?

Does Jade Biosciences stock pay dividends?

When is the next Jade Biosciences dividend payment date?

What is the beta indicator for Jade Biosciences?